Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EPS (Weighted Average and Diluted) (2016 - 2025)

Anaptysbio's EPS (Weighted Average and Diluted) history spans 9 years, with the latest figure at $1.7 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 357.58% year-over-year to $1.7; the TTM value through Dec 2025 reached -$0.4, up 92.23%, while the annual FY2025 figure was -$0.46, 91.02% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.7 in Q4 2025 per ANAB's latest filing, up from $0.52 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.7 in Q4 2025 to a low of -$1.71 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.92, with a median of -$1.18 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 5650.0% in 2022, then surged 357.58% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.19 in 2021, then rose by 21.85% to -$0.93 in 2022, then plummeted by 70.97% to -$1.59 in 2023, then soared by 58.49% to -$0.66 in 2024, then skyrocketed by 357.58% to $1.7 in 2025.
  • Per Business Quant, the three most recent readings for ANAB's EPS (Weighted Average and Diluted) are $1.7 (Q4 2025), $0.52 (Q3 2025), and -$1.34 (Q2 2025).